RNLXY Renalytix plc
Services-Medical Laboratories · OTC · SEC CIK 1811115 · Fiscal year ends 06/30
Financial factors as of 2024-03-31 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-40.2%
TTM net income YoY5.5%
TTM EPS YoY30.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-1.6%
Operating margin-1,531.6%
Net margin-1,687.8%
FCF margin—
EBITDA margin-1,515.1%
Returns
ROE-1,073.2%
ROA-154.4%
ROIC (approx.)—
Asset turnover0.09x
Leverage & solvency
Liabilities / assets226.7%
Debt / equity—
Current ratio0.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-27.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q12024-09-30 | 2024Q4*2024-06-30 | 2024Q32024-03-31 | 2024Q22023-12-31 | 2024Q12023-09-30 | 2023Q4*2023-06-30 | 2023Q32023-03-31 | 2023Q22022-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $522,000 | $586,000 | $535,000 | $709,000 | $459,000 | $518,000 | $724,000 | $1.19M |
| Cost of revenue | $422,000 | $550,000 | $601,000 | $480,000 | $502,000 | $673,000 | $603,000 | $711,000 |
| Gross profit | $100,000 | $36,000 | -$66,000 | $229,000 | -$43,000 | -$155,000 | $121,000 | $481,000 |
| R&D expense | $921,000 | $1.06M | $2.22M | $3.23M | $2.79M | $3.27M | $3.94M | $3.33M |
| SG&A expense | $3.27M | $4.50M | $3.85M | $5.34M | $6.06M | $6.51M | $7.09M | $6.81M |
| Operating income | -$4.09M | -$5.53M | -$6.55M | -$8.64M | -$8.89M | -$9.93M | -$10.92M | -$9.65M |
| Pretax income | -$4.73M | -$7.07M | -$7.74M | -$8.48M | -$10.15M | -$11.10M | -$12.11M | -$10.44M |
| Income tax | $2,000 | $0 | $0 | $4,000 | $0 | $4,000 | -$1,000 | $0 |
| Net income | -$4.73M | -$7.07M | -$7.74M | -$8.48M | -$10.15M | -$11.10M | -$12.11M | -$10.44M |
| EBITDA | -$4.03M | -$5.46M | -$6.53M | -$8.54M | -$8.76M | -$9.81M | -$10.82M | -$9.55M |
| EPS (basic) | -0.04 | — | -0.08 | -0.09 | -0.11 | — | -0.14 | -0.14 |
| EPS (diluted) | -0.04 | — | -0.08 | -0.09 | -0.11 | — | -0.14 | -0.14 |
| Weighted avg. shares (diluted) | 105.70M | — | 97.65M | 97.27M | 94.77M | — | 85.56M | 74.89M |
| Balance sheet | ||||||||
| Cash & equivalents | $909,000 | $4.68M | $4.70M | $5.62M | $13.89M | $24.68M | $33.03M | $23.82M |
| Receivables | $902,000 | $722,000 | $554,000 | $1.37M | $1.01M | $776,000 | $747,000 | $820,000 |
| Current assets | $2.88M | $6.12M | $6.34M | $8.25M | $16.47M | $26.88M | $35.73M | $26.60M |
| PP&E, net | $202,000 | $216,000 | $230,000 | $576,000 | $944,000 | $1.03M | $2.19M | $2.29M |
| Intangibles | $869,000 | $869,000 | $913,000 | $965,000 | $974,000 | $1.05M | $1.09M | $1.13M |
| Total assets | $4.79M | $7.97M | $8.77M | $11.28M | $19.54M | $30.63M | $39.80M | $30.66M |
| Current liabilities | $12.01M | $11.49M | $14.99M | $13.92M | $15.17M | $16.14M | $14.68M | $14.29M |
| Total liabilities | $16.11M | $15.83M | $19.88M | $19.23M | $21.03M | $23.66M | $21.70M | $21.77M |
| Shareholders' equity | -$11.32M | -$7.85M | -$11.11M | -$7.96M | -$1.49M | $6.97M | $18.10M | $8.88M |
| Shares outstanding | 165.93M | 154.37M | 119.92M | 99.93M | 93.78M | 93.78M | 93.78M | 74.89M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.84M | -$7.83M | -$4.86M | -$7.92M | -$9.50M | -$8.63M | -$10.10M | -$8.23M |
| Capital expenditure | — | — | — | — | — | $0 | $0 | $0 |
| Free cash flow | — | — | — | — | — | -$8.63M | -$10.10M | -$8.23M |
| Investing cash flow | $23,000 | -$1,000 | -$3,000 | $0 | $0 | $59,000 | $5,000 | -$64,000 |
| Financing cash flow | $0 | $7.79M | $4.03M | -$507,000 | -$1.06M | -$98,000 | $18.02M | -$588,000 |
| Depreciation & amortization | $60,000 | $60,000 | $20,000 | $100,000 | $127,000 | $120,000 | $100,000 | $100,000 |
| Stock-based compensation | $254,000 | $419,000 | $385,000 | $385,000 | $523,000 | $574,000 | $770,000 | $815,000 |
Free plan shows the latest 8 periods; Pro shows all 18 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.